+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2028

  • ID: 4755940
  • Report
  • December 2021
  • Region: Global
  • 214 Pages
  • Meticulous Market Research Pvt. Ltd.

FEATURED COMPANIES

  • CLARIVATE PLC
  • Flatiron Health
  • ICON plc
  • Medpace Holdings Inc.
  • PerkinElmer Inc.
  • SAS Institute Inc.
Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)-Forecast to 2028

The RWE solutions market is expected to grow at a CAGR of 11.8% from 2021to 2028 to reach $4.4 billion by 2028

Following a thorough primary and secondary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, opportunities, and challenges.

Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to-end RWE services, and the rising adoption of wearable devices and AI in RWE.

Based on component, the datasets segment is expected to command the largest share of the global RWE solutions market due to factors such as the rising dependence of outcome-based studies on real-world data, increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Based on application, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period. The increasing investments by pharma and biopharma companies in R&D, increasing demand for real-world data and real-world evidence for accelerating drug discovery and development, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE) are the factors contributing to the growth of this segment.

Based on end user, the pharmaceutical, biotechnology, & medical device companies segment is expected to witness the fastest growth rate during the forecast period. The increasing importance of RWE studies in drug development &approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings are the factors contributing to the growth of this segment.

An in-depth analysis of the geographical scenario of the RWE solutions market provides detailed qualitative and quantitative insights about the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific and Europe.

The key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report


Global RWE Solutions Market, by Component

  • Datasets
  • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Other Disparate Datasets
  • Integrated Datasets
  • Consulting & Analytics
(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

Global RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Other Applications
(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

Global RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users
(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

Global RWE Solutions Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • CLARIVATE PLC
  • Flatiron Health
  • ICON plc
  • Medpace Holdings Inc.
  • PerkinElmer Inc.
  • SAS Institute Inc.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Burden of Chronic Diseases
4.2.2. Rising Focus Towards Personalized Healthcare
4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
4.2.4. Shift Towards Value-Based Care
4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Rising Focus on End-To-End RWE Services
4.4.3. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
4.5. Challenges
4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Impact Assessment of COVID-19
4.7. Key Market Trends
4.7.1. Growing Adoption of RWE in Drug Development and Commercialization
4.7.2. Rising Number of Consolidations
4.7.3. Improved Patient Outcomes and value Creation from real world Evidence

5. Regulatory Analysis - Real-World Evidence (RWE) Solutions Market
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. Rest of the World

6. Pricing Models (Emr/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based Pricing)
6.3. Pay Per Usage (Value-Based Pricing)
6.4. Annual Subscription

7. Global Real-World Evidence Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Product/Disease Registries Data
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting & Analytics

8. Global Real-World Evidence Solutions Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Post Market Surveillance
8.5. Medical Device Development & Approvals
8.6. Other Applications

9. Global Real-World Evidence Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users

10. Global Real-World Evidence Solutions Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Taiwan
10.4.6. Singapore
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa

11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2020)
11.4.1. IQVIA Holdings, Inc. (U.S.)
11.4.2. Icon Plc (Ireland)
11.4.3. PPD, Inc.

12. Company Profiles
12.1. IQVIA Holdings Inc.
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Strategic Developments
12.2. PPD, Inc.
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.2.4. Strategic Developments
12.3. ICON plc
12.3.1. Business Overview
12.3.2. Financial Overview
12.3.3. Product Portfolio
12.3.4. Strategic Developments
12.4. SYNEOS HEALTH, INC.
12.4.1. Business Overview
12.4.2. Financial Overview
12.4.3. Product Portfolio
12.4.4. Strategic Developments
12.5. CLARIVATE PLC
12.5.1. Business Overview
12.5.2. Financial Overview
12.5.3. Product Portfolio
12.6. Medpace Holdings Inc.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.3. Product Portfolio
12.7. Symphony Innovation, LLC
12.7.1. Business Overview
12.7.2. Product Portfolio
12.7.3. Strategic Developments
12.8. PAREXEL International Corporation
12.8.1. Business Overview
12.8.2. Product Portfolio
12.8.3. Strategic Developments
12.9. IBM Corporation
12.9.1. Business Overview
12.9.2. Financial Overview
12.9.3. Product Portfolio
12.9.4. Strategic Developments
12.10. UnitedHealth Group Incorporated
12.10.1. Business Overview
12.10.2. Financial Overview
12.10.3. Product Portfolio
12.11. Flatiron Health
12.11.1. Business Overview
12.11.2. Product Portfolio
12.11.3. Strategic Developments
12.12. Oracle Corporation
12.12.1. Business Overview
12.12.2. Financial Overview
12.12.3. Product Portfolio
12.13. SAS Institute, Inc.
12.13.1. Business Overview
12.13.2. Product Portfolio
12.13.2. Strategic Developments
12.14. Clinigen Group plc
12.14.1. Business Overview
12.14.2. Financial Overview
12.14.3. Product Portfolio
12.15. Cognizant Technology Solutions Corporation
12.15.1. Business Overview
12.15.2. Financial Overview
12.15.3. Product Portfolio
12.16. PerkinElmer, Inc.
12.16.1. Business Overview
12.16.2. Financial Overview
12.16.3. Product Portfolio

13. Appendix
13.1. Questionnaire
13.2. Available Customization
Note: Product cover images may vary from those shown

Loading
LOADING...

  • IQVIA Holdings Inc.
  • ICON plc
  • PPD Inc.
  • SYNEOS HEALTH Inc.
  • CLARIVATE PLC
  • Medpace Holdings Inc.
  • Symphony Innovation LLC
  • Clinigen Group plc
  • Cognizant Technology Solutions Corporation
  • IBM Corporation
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer Inc.
  • SAS Institute Inc.
  • UnitedHealth Group Incorporated
  • Flatiron Health
Note: Product cover images may vary from those shown